- Home
- GBX vs OCS Comparison
GBX vs OCS Comparison
Compare GBX & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GBX | OCS |
|---|---|---|
| Founded | 1974 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GBX | OCS |
|---|---|---|
| Price | $52.43 | $28.30 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $49.00 | $39.57 |
| AVG Volume (30 Days) | ★ 586.8K | 310.1K |
| Earning Date | 01-08-2026 | 03-10-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | ★ 0.79 | N/A |
| EPS | ★ 5.77 | N/A |
| Revenue | ★ $3,070,400,000.00 | $991,999.00 |
| Revenue This Year | N/A | $14.53 |
| Revenue Next Year | N/A | $691.13 |
| P/E Ratio | $8.89 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $37.77 | $14.00 |
| 52 Week High | $66.29 | $29.36 |
Technical Indicators
Market Signals| Indicator | GBX | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 64.28 | 74.43 |
| Support Level | $48.21 | $27.41 |
| Resistance Level | $51.82 | $29.36 |
| Average True Range (ATR) | 1.34 | 1.30 |
| MACD | 0.06 | 0.20 |
| Stochastic Oscillator | 96.82 | 82.18 |
Price Performance
Historical ComparisonAbout GBX Greenbrier Companies Inc. (The)
Greenbrier Companies Inc supplies equipment and services to international freight transportation markets, designing and marketing freight railcars in North America, Europe, and Brazil through subsidiaries and joint ventures. It provides railcar wheel services, parts, maintenance, and conversion services in North America. The company owns a lease fleet sourced mainly from its manufacturing operations and offers railcar management, regulatory compliance, and leasing services to railroads and owners. It operates two segments: Manufacturing and Leasing & Fleet Management, with the majority of revenue from Manufacturing. The company operates in the U.S. and internationally, with the majority of revenue from the U.S. market.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.